The number of OI cases and associated costs averted if ART was initiated at a CD4 count ≥200 cells/μL were estimated using Joint United Nations Programme on HIV/AIDS (UNAIDS) country estimates and global average OI treatment cost per case. The gene discussed is CD4; the disease is osteogenesis imperfecta.